Khalid Islam - 12 Jun 2023 Form 4 Insider Report for FENNEC PHARMACEUTICALS INC. (FENC)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
13 Jun 2023, 12:39:51 UTC
Prior SEC filing
22 Sep 2022
Next SEC filing
26 Jun 2023
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Khalid Islam

Key filing fact

Khalid Islam filed Form 4 for FENNEC PHARMACEUTICALS INC. (FENC) on 13 Jun 2023.

Key facts

  • This page summarizes Khalid Islam's Form 4 filing for FENNEC PHARMACEUTICALS INC. (FENC).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 13 Jun 2023, 12:39.

Change

  • Previous filing in this sequence was filed on 22 Sep 2022.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

FENC transaction Derivative

Stock Option

Award

Transaction value
$0
Shares
+25,000
Change %
+6.9%
Price
$0.000000
Shares after
388,825
Date
12 Jun 2023
Ownership
Direct
Underlying class
Common Shares
Underlying amount
25,000
Exercise price
$8.78
Footnotes
F1, F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

On June 12, 2023, Khalid Islam was granted a non-qualified stock option to purchase 25,000 shares of the issuer's common shares pursuant to the issuer's Equity Incentive Plan.

Footnote F2

The option is 100% vested of date of grant.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .